'Antithrombotic Drug Market Will Rise to 24.4 Billion Dollars in 2015' Says Visiongain

LONDON, January 19, 2012 /PRNewswire/ --

A new report by visiongain predicts that the overall world antithrombotic and anticoagulant drug market will reach 24.4 billion dollars in 2015. That forecast appears in Antithrombotic/Anticoagulant Drugs: World Market 2012-2022, published in January 2012. Visiongain is a business information provider based in London, UK.

The new study assesses drugs to treat abnormal blood clotting in human beings. It predicts that the industry and market for blood thinners will soon recover from the patent expiries of two leading drugs, Plavix and Lovenox. The overall world antithrombotic treatments market will show a gradual increase in sales revenues to 2022. Supporting that expansion will be increasing disease incidence, prevalence and diagnosis, especially in the developing markets of China and India.

The pharmaceutical industry analyst at visiongain, said: "The launch of new oral anticoagulants with better safety and efficacy profiles, easier dosing regimens and compliance- facilitating delivery methods will be welcome in the market. These drugs are likely to replace some older treatments. There are unmet needs in this medical area. Pharmaceutical companies will further explore this field, making progress this decade. Blood thinners will play important roles in medicine, helping to prevent and treat cardiovascular disorders."

This study forecasts revenues of ten leading drugs in the antithrombotic agents market, including Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra and Aspirin Cardio. The report also predicts revenues of newly launched drugs: Brilinta, Xarelto, Pradaxa and Effient. Analyses and discussions cover activities of Eli Lilly, Boehringer Ingelheim, AstraZeneca, J&J, Bayer, Sanofi, Merck, Eisai, Daiichi Sankyo and other pharmaceutical companies.

In addition to forecasting the overall world market and leading national markets, the work predicts revenue trends for submarkets. It forecasts sales of platelet aggregation inhibitors, heparins, fibrinolytics, vitamin K antagonists, direct thrombin inhibitors and direct factor Xa inhibitors. The report provides revenue values to 2022 at world market, therapeutic class, product and national levels.

The antithrombotic drug market is expanding. Safer and more efficacious drugs are in demand. Also in demand are antidotes to stop excessive bleeding after treatment. This new report discusses market drivers, restraints and opportunities of revenue growth for blood-thinning drugs. It adds to visiongain's wide range of analytical research on industries and markets in healthcare, including the treatment of cardiovascular disorders.

To view sample pages please click on:

http://www.visiongain.com/Report/743/Antithrombotic-Anticoagulant-Drugs-World-Market-2012-2022

Please contact Sara Peerun for an exec summary:
Email: sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

1. Executive Summary
1.1 Antithrombotic/Anticoagulant Drug: World Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Blood Clotting: Mechanism, Disorders and Treatments
2.1 Thrombosis
2.1.1 Venous Thrombosis
2.1.2 Arterial Thrombosis
2.2 Complications of Thrombosis
2.2.1 Pulmonary Embolism
2.2.2 Stroke
2.2.3 Myocardial Infarction
2.2.4 Acute Coronary Syndrome
2.3 Antithrombotic Treatments
2.3.1 Platelet Aggregation Inhibitors
2.3.1.1 Glycoprotein Inhibitors
2.3.1.2 Aspirin
2.3.1.3 Thienopyridines
2.3.2 Heparins
2.3.3 Fibrinolytics
2.3.3.1 Streptokinase and Urokinase
2.3.3.2 Tissue Plasminogen Activator (tPA)
2.3.3.3 Other Thrombolytic Agents
2.3.4 Vitamin K Antagonists
2.3.5 Direct Thrombin Inhibitors
2.3.6 Direct Factor Xa Inhibitors

3. Antithrombotic Drugs: World Market 2012-2022
3.1 The Antithrombotic/Anticoagulant Drug Market in 2010
3.2 The Antithrombotic/Anticoagulant Drug Market Forecast 2012-2022
3.3 The Leading Antithrombotic/Anticoagulant Therapeutic Classes
3.3.1 The Leading Therapeutic Classes in 2010
3.3.2 Leading Therapeutic Class Forecast 2012-2022
3.4 Platelet Aggregation Inhibitors
3.4.1 Platelet Aggregation Inhibitors Dominated the Market in 2010
3.4.2 Platelet Aggregation Inhibitors: Market Forecast 2012-2022
3.5 Heparins
3.5.1 The Heparins Market in 2010
3.5.2 Heparins: Market Forecast 2012-2022
3.6 Fibrinolytics
3.6.1 The Fibrinolytics Market in 2010
3.6.2 Fibrinolytics: Market Forecast 2012-2022
3.7 Vitamin K Antagonists
3.7.1 Vitamin K Antagonists Market in 2010
3.7.2 Vitamin K Antagonists Market Forecast 2012-2022
3.8 Direct Thrombin Inhibitors
3.8.1 Direct Thrombin Inhibitors Market in 2010
3.8.2 Direct Thrombin Inhibitors: Market Forecast 2012-2022
3.9 Direct Factor Xa Inhibitors
3.9.1 Direct Factor Xa Inhibitors Market in 2010
3.9.2 Direct Factor Xa Inhibitors: Market Forecast 2012-2022
3.10 Chapter Summary

4. Leading National Markets for Antithrombotic/Anticoagulant Drugs, 2012-2022
4.1 Leading National Markets in 2010
4.2 Leading National Markets: Forecasts to 2022
4.3 The US Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.4 The Japanese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.5 Leading European Antithrombotic/Anticoagulant Drug Markets, 2012-2022
4.6 The Chinese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.7 The Indian Antithrombotic/Anticoagulant Drug Market, 2012-2022

5. Leading Antithrombotic/Anticoagulant Drugs, 2012-2022
5.1 The Leading Drugs of 2010
5.2 Plavix - Commercial Prospects
5.2.1 Plavix: The Leading Anticoagulant of 2010
5.2.2 Plavix Sales Forecast, 2012-2022
5.2.3 Generic Competition
5.2.4 Branded Competition
5.3 Lovenox
5.3.1 Lovenox Sales Forecast, 2012-2022
5.3.2 Competition for Lovenox
5.4 Pletal
5.4.1 Pletal Sales, 2010
5.4.2 Pletal Sales Forecast, 2012-2022
5.5 Fragmin
5.5.1 Fragmin Sales, 2010
5.5.2 Fragmin Sales Forecast, 2012-2022
5.6 Asasantin
5.6.1 Asasantin Sales, 2010
5.6.2 Asasantin Sales Forecast, 2012-2022
5.7 Arixtra
5.7.1 Arixtra Sales, 2010
5.7.2 Arixtra Sales Forecast, 2012-2022
5.8 Aspirin Cardio
5.8.1 Aspirin Cardio Sales, 2010
5.8.2 Aspirin Cardio Sales Forecast, 2012-2022
5.9 Opalmon
5.9.1 Opalmon Sales, 2010
5.9.2 Opalmon Sales Forecast, 2012-2022
5.10 Angiomax
5.10.1 Angiomax Sales, 2010
5.10.2 Angiomax Sales Forecast, 2012-2022
5.11 Activase
5.11.1 Activase Sales, 2010
5.11.2 Activase Sales Forecast, 2012-2022
5.12 Newly Launched Drugs, 2009-2011
5.12.1 Eli Lilly's Effient
5.12.1.1 Effient Sales Forecast, 2012-2022
5.12.1.2 Competition for Effient
5.12.2 Boehringer Ingelheim's Pradaxa
5.12.2.1 Pradaxa Sales Forecast, 2012-2022
5.12.2.2 Competition for Pradaxa
5.12.3 AstraZeneca's Brilinta
5.12.3.1 Brilinta Sales Forecast, 2012-2022
5.12.3.2 Competition for Brilinta
5.12.4 Johnson & Johnson/Bayer's Xarelto
5.12.4.1 Xarelto Sales Forecast, 2012-2022
5.12.4.2 Competition for Xarelto
5.13 Chapter Summary

6. Antithrombotic/Anticoagulant Drug R&D Pipeline
6.1 Platelet Aggregation Inhibitors R&D Pipeline, 2011
6.1.1 Portola/Novartis's Elinogrel
6.2 Heparins R&D Pipeline, 2011
6.2.1 Sanofi's Semuloparin
6.3 Fibrinolytics R&D Pipeline, 2011
6.3.1 Lundbeck/Berlex/Bayer's Desmoteplase
6.4 Direct Thrombin Inhibitors R&D Pipeline, 2011
6.4.1 Merck's Vorapaxar
6.4.2 Eisai's Atopaxar
6.5 Direct Factor Xa Inhibitors R&D Pipeline, 2011
6.5.1 BMS/Pfizer's Apixaban
6.5.2 Portola's Betrixaban
6.5.3 Daiichi Sankyo's Edoxaban
6.6 R&D Pipeline for Other Antithrombotic Drugs, 2011
6.6.1 Endotis/Merck's EP217609

7. SWOT and STEP Analyses
7.1 Principal Market Drivers
7.1.1 Rising Disease Prevalence
7.1.2 Risk Factors: Management Rather Than Cure
7.1.3 Opportunities for Continuous Growth
7.1.3.1 Standing Out from Competitors
7.1.3.2 Cost-Effective Replacement of Warfarin
7.1.3.3 Antidotes in Demand
7.1.3.4 Further Development of Existing Drugs
7.1.3.5 Exploring New Markets
7.1.4 Advances in Technology Will Bring Benefits to the Market
7.2 Principal Market Restraints
7.2.1 Highly Competitive Market
7.2.1.1 Generic Competition
7.2.1.2 Branded Competition
7.2.2 Cost-Reduction Pressure
7.2.3 Stringent Regulations

8. Research Interviews
8.1 Interview with Dr Charles E. Mahan (Director of Outcomes Research, New Mexico Heart Institute, Albuquerque, New Mexico)
8.1.1 Unmet Needs
8.1.2 Major Areas of Focus
8.1.3 New Drug Potential
8.1.4 Key Market Drivers
8.1.5 Opportunities for Revenue Growth
8.2 Interview with Dr Maurice Petitou (Head of Preclinical Research and Development, Endotis Pharma)
8.2.1 EP217609: The First Neutralizable Anticoagulant
8.2.2 Drug Targets Worth Exploring
8.2.3 New Drug Potential
8.2.4 Unmet Needs
8.3 Interview with Dr Jonathan L. Halperin (Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York)
8.3.1 Unmet Needs
8.3.2 New Findings
8.3.3 Warfarin Replacement
8.3.4 Areas Demanding Attention
8.3.5 Key Market Restraints
8.4 Interview with Dr Jeffrey I. Weitz (Professor of Medicine & Biochemistry, McMaster University, and Executive Director, Thrombosis & Atherosclerosis Research Institute, Ontario)
8.4.1 Unmet Needs
8.4.2 New Oral Anticoagulants
8.4.3 Future Areas of Focus
8.4.4 New Drug Potential
8.4.5 Market Drivers and Restraints

9. Conclusions
9.1 World Market Overview to 2022
9.2 Leading Drug Classes
9.3 Leading Products
9.4 Leading National Markets
9.5 The Future of the Antithrombotic/Anticoagulant Drug Market
9.5.1 Challenges
9.5.2 Opportunities

Companies Listed

Abbott
Ablynx
Acino Pharma
ARCA Discovery
Archemix
Arena Pharmaceuticals
Artisan Pharma
Asahi Kasei Pharma
AstraZeneca
ARYx Therapeutics
Barr Pharmaceuticals
Bayer Healthcare
Berlex
Bharat Biotech
BioInvent
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Canyon Pharmaceuticals
Cardiome Pharma
Center for Medicaid and Medicare Services
Daiichi Sankyo
Dainippon Sumitomo
Dr. Reddy's Laboratories
Eisai Pharmaceuticals
Eli Lilly
Endotis Pharma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Genentech
GlaxoSmithKline (GSK)
Janssen
Johnson & Johnson (J&J)
Kowa
Kyowa Hakko
LIMES Institute
Lundbeck
McMaster University
Merck & Co.
Mitsubishi Kasei
Momenta
Myriad Genetics
New Mexico Heart Institute
Novartis
Ono Pharmaceutical
Organon
Otsuka Pharmaceuticals
PAION
Pfizer
Pharmacia
Pharmacyclics
Polymedix
Portola Pharmaceuticals
POZEN
Ranbaxy
Regado Biosciences
Roche
Rovi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Speedel
Takeda Pharmaceutical
Talecris Biotherapeutics
Teva Pharmaceuticals
The Medicines Company
The Mount Sinai Medical Center
Trigen Pharma
ThromboGenics
Thrombosis & Atherosclerosis Research Institute, Ontario
Virginia Commonwealth University
Watson Pharmaceuticals
Western Therapeutics Institute
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center

Notes for Editors

About visiongain

Visiongain is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100